<DOC>
	<DOC>NCT00960076</DOC>
	<brief_summary>The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.</brief_summary>
	<brief_title>An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetics taking metformin IR or XR greater than or equal to 850mg and less than or equal to 1500mg only for at least 8 weeks prior to screening A1c: 7.511% (at screening) BMI less than or equal to 45 kg/m2 Significant cardiovascular history Active liver disease, renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>T2DM</keyword>
	<keyword>Metformin</keyword>
	<keyword>A1c</keyword>
</DOC>